tldrdailynews.com logo

GLP-1 diabetes medicines show potential to curb Alzheimer's protein buildup in preclinical studies

1 min read
Source: ScienceAlert
GLP-1 diabetes medicines show potential to curb Alzheimer's protein buildup in preclinical studies
Photo: ScienceAlert
TL;DR

A new review of mostly preclinical studies links GLP-1 diabetes/weight-loss medications (e.g., semaglutide, liraglutide) to reduced amyloid-beta plaques and tau tangles in cells and animals, with only two small human trials reporting mixed results; still early evidence and larger clinical trials are needed to confirm cognitive benefits.

Topics:health#alzheimers-disease#amyloid-beta#clinical-trials#glp-1-drugs#health#tau-proteins
Share this article
  1. Weight-Loss Drugs May Reduce Buildup of Alzheimer's Proteins, Major Review Finds  ScienceAlert
  2. Weight-loss drugs could tackle Alzheimer's—study  Medical Xpress
  3. ASK THE DOCTORS: Researching GLP-1 Drugs and Parkinson's Progression  Marietta Daily Journal
  4. GLP-1 Dementia, Alzheimer’s Disease Risks Questioned in New Study  AboutLawsuits.com
  5. GLP-1 Drugs and Brain Health: Can They Reduce Alzheimer’s Risk?  Being Patient

Want the full story? Read the original reporting

Read on ScienceAlert